CRISPR ruling means legal fight will continue

A ruling by the U.S. Court of Appeals for the Federal Circuit promises to extend the legal battle over which party owns the use of CRISPR in eukaryotic cells.

In another victory for The Broad Institute of MIT and Harvard, the CAFC affirmed Monday a ruling from the U.S. Patent Trial and Appeal Board (PTAB) that Broad's patent covering CRISPR-Cas9 gene editing technology with co-inventor Feng Zhang does not interfere with CRISPR IP

Read the full 724 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers